Blood Clot News and Research

RSS

A Blood Clot is a mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.

Women at high risk of developing breast cancer reluctant to take tamoxifen for prevention

Even when women at high-risk of breast cancer are well-informed about the risks and benefits of using the drug tamoxifen for prevention, only 6 percent said they were likely to take it.

2 Dec 2009

Pulmonary embolism can be diagnosed by combining SPECT and low-dose CT, shows research

When it comes to diagnosing pulmonary embolism-a sudden blockage in the lung artery that could be deadly if not treated-which technique is the most effective?

2 Dec 2009

MHI performs its first Amptlazer- Cardiac Plug implant

A multidisciplinary team from the Montreal Heart Institute (MHI), which is affiliated to the Universit- de Montr-al, performed its first catheter implantation of a new prosthesis (Amptlazer- Cardiac Plug) closing the appendage of the left atrium of the heart, which will have the effect of preventing the formation of blood clots and avoiding open-heart surgery.

1 Dec 2009

Amgen to present updated data on Nplate at the 2009 ASH meeting

Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

1 Dec 2009

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

A multidisciplinary team from the Montreal Heart Institute (MHI) performed its first catheter implantation of a new prosthesis (Amptlazer(R) Cardiac Plug) closing the appendage of the left atrium of the heart, which will have the effect of preventing the formation of blood clots and avoiding open-heart surgery. This is excellent news for patients suffering from atrial fibrillation, the most common form of cardiac arrhythmia, affecting at least 5% of Canadians over the age of 70.

30 Nov 2009

Health Canada announces recent changes made to heparin manufacturing standards

Health Canada is informing health care professionals and Canadians of recent changes to heparin manufacturing standards in the United States that will result in a decrease in the potency of certain heparin products by about 10 per cent.

27 Nov 2009

UCLA engineers and physicians develop PAD treatment device to prevent thrombosis

A fortuitous discovery that grew out of a collaboration between UCLA engineers and physicians could potentially offer hope to the nearly 10 million Americans who suffer from peripheral arterial disease.

26 Nov 2009

Cardiovascular risks associated with taking Vioxx could have been identified earlier, say researchers

Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market.

24 Nov 2009

New data indicates early association between anti-inflammatory medication and cardiovascular risk

Clinical trial data indicated an association between the anti-inflammatory medication rofecoxib and cardiovascular risk as early as December 2000, before the product was taken off the market in September 2004, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Nov 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

New computational tool may aid surgeons plan for life-saving pediatric operation

A team of researchers at the University of California, San Diego and Stanford University has developed a way to simulate blood flow on the computer to optimize surgical designs. It is the basis of a new tool that may help surgeons plan for a life-saving operation called the "Fontan" surgery, which is performed on babies born with severe congenital heart defects.

24 Nov 2009

Updated clinical guidelines on Effient treatment for ACS patients

Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack.

19 Nov 2009

FDA: Plavix-Prilosec combination may reduce anti-clotting effect

Patients should avoid using the stomach acid reducer Prilosec/Prilosec OTC (omeprazole) with the anti-clotting drug Plavix (clopidogrel), the U.S. Food and Drug Administration warned on Nov. 17.

19 Nov 2009

Key findings from AstraZeneca's phase II studies of ticagrelor

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.

18 Nov 2009

Novel device may reduce ischemic stroke damage

Stroke researchers at the Methodist Neurological Institute in Houston are the only ones in Texas to offer a novel device that might extend the acute stroke treatment window from three hours to 24.

18 Nov 2009

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

17 Nov 2009

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

Results of a Mayo Clinic study show the incidence of stroke or mini-stroke related to a coronary angioplasty (http://www.mayoclinic.org/heart-catheterization/types.html) remained steady over a 15-year period. Researchers say this is good news because physicians now are performing the artery-opening procedure on older patients who are sicker and need more complicated treatment.

17 Nov 2009

Hospitals should expand quality control guidelines to improve surgical complications in older patients

The elderly are more vulnerable to problems after a major surgical procedure than younger patients, but a team of investigators using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) suggest that one way to improve surgical results in this age group is to have hospitals expand their quality control guidelines to include more types of surgery-related complications.

17 Nov 2009

Migraine headaches linked with increased risk of common kind of stroke

Pooling results from 21 studies, involving 622,381 men and women, researchers at Johns Hopkins have affirmed that migraine headaches are associated with more than twofold higher chances of the most common kind of stroke: those occurring when blood supply to the brain is suddenly cut off by the buildup of plaque or a blood clot.

16 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

Blood Clot News and Research

Further Reading

Women at high risk of developing breast cancer reluctant to take tamoxifen for prevention

Pulmonary embolism can be diagnosed by combining SPECT and low-dose CT, shows research

MHI performs its first Amptlazer- Cardiac Plug implant

Amgen to present updated data on Nplate at the 2009 ASH meeting

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

Health Canada announces recent changes made to heparin manufacturing standards

UCLA engineers and physicians develop PAD treatment device to prevent thrombosis

Cardiovascular risks associated with taking Vioxx could have been identified earlier, say researchers

New data indicates early association between anti-inflammatory medication and cardiovascular risk

Lysteda tablets to treat menorrhagia approved by the FDA

New computational tool may aid surgeons plan for life-saving pediatric operation

Updated clinical guidelines on Effient treatment for ACS patients

FDA: Plavix-Prilosec combination may reduce anti-clotting effect

Key findings from AstraZeneca's phase II studies of ticagrelor

Novel device may reduce ischemic stroke damage

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

Hospitals should expand quality control guidelines to improve surgical complications in older patients

Migraine headaches linked with increased risk of common kind of stroke

FDA approves Lysteda for treating menorrhagia

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News